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Perceived medication adverse effects and coping
strategies reported by chronic heart failure patients
R. H. E. De Smedt,1 P. Denig,1,2 F. M. Haaijer-Ruskamp,1,2 T. Jaarsma3
Introduction
Chronic heart failure (CHF) is a disabling progres-
sive condition, which is a significant problem for
both those suffering from the disease and the health-
care professional. Over the past few decades, tremen-
dous gains have been achieved both in
pharmacological and in technological treatment for
patients with CHF. As a result, CHF patients are
commonly exposed to a lifelong treatment with mul-
tiple drugs, often requiring inconvenient medication
schedules and frequent changes in treatment. It has
been shown that adequate drug treatment is associ-
ated with fewer cardiovascular hospitalisations (1),
but polypharmacy may also cause more drug-
induced adverse events as well as more drug-drug
interactions (2). Because of older age, CHF patients
are also at higher risk for experiencing adverse drug
events because of age-associated changes in pharma-
cokinetics and pharmacodynamics (2,3).
There is little information available regarding
adverse effects (AEs) perceived by CHF patients in
daily practice. Data on drug safety and more in par-
ticular, on adverse drug events of CHF patients are
primarily based on results of randomised clinical
trails. These commonly reflect objectively evaluated
adverse events in a selective patient population,
which are likely to differ from the subjective AEs
patients may experience in everyday practice. Evi-
dence is emerging that adverse drug events are often
SUMMARY
Background: Data on medication adverse effects (AEs) in chronic heart failure
(CHF) are primarily based on results from clinical trials. Little is known about AEs
perceived by CHF patients in daily practice and how patients deal with these sub-
jective AEs. Aims: To describe the scope and nature of perceived AEs of CHF
patients, their coping strategies and the relationship of perceived AEs to medica-
tion, patient characteristics and quality of life. Methods: This cross-sectional
observational study included a sample of 680 patients previously hospitalised for
CHF. Perceived AEs and coping strategies were collected by interviews based on a
structured questionnaire. Medication and clinical information were collected by
chart review. Results: Of the 670 CHF patients completing the questionnaire,
17% reported at least one AE. In total, 186 AEs were reported of which 15%
could not be linked to any medication. Nausea (4%), dizziness (4%), itches (3%)
and rash (3%) were the most prevalent. The drug associated with the highest AE
rate was pravastatin (27%). On average, more than five different drugs could be
related to the AEs headache, dizziness and nausea. Patients reporting AEs had a
lower general health perception, younger age and were more often using antiar-
rhythmic drugs. Of patients experiencing AEs, 69% conferred with their doctor,
24% reported having done nothing in reaction and 2% discontinued their medica-
tion without discussing it with the doctor. Conclusion: Adverse effects are fre-
quently perceived by CHF patients, but they are difficult to recognise and manage
in daily practice.
What’s known
• Data on drug safety are primarily based on the
results from clinical trials, where the patients
included often have less comorbidity and
comedication than the patients using the drugs in
everyday practice.
• It has been estimated that at least 5–10% of
patients in clinical trials discontinue use of
placebo because of perceived adverse effects
(AEs).
• Perceived AEs are often reported as a common
reason for non-adherence in CHF.
• Patient characteristics associated with AEs of
medication are the number of coexisting
conditions and the number of concurrently used
medications.
What’s new
• The overall rate of AEs reported by patients of
17% is higher than detected by reports from
healthcare providers or observed in clinical trials.
• Socio-demographic and clinical variables have
little capability in predicting the risk of perceiving
AEs in patients with CHF.
• Up to one-third of the patients experiencing an
AE did not communicate the AE with the
healthcare provider.
• Perceived AEs may be attributed to several
different medications, underlining the complexity
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inadequately reported in clinical trials (4). The
reported prevalence of common physical symptoms,
such as headache or fatigue, is usually much lower in
clinical trials than would be expected from epidemio-
logical survey data (5). Additionally, clinical trials
often include patients with less comedication, com-
orbidities and other conditions that may increase the
perceived AEs in comparison to patients using the
drugs in everyday practice.
In daily practice, however, perceived AEs have
been reported as a common reason for non-adher-
ence in CHF (6,7). This may lead to decompensation
requiring emergency hospitalisation (8,9) and to
increased mortality and morbidity rates, impaired
quality of life and increased healthcare costs (10). On
the other hand, patients may also decide to continue
taking a drug despite perceived AEs. Little is known
about the different coping strategies the CHF
patients may use to manage the perceived AEs of
medication.
To improve the management of adverse drug
effects, it is important to increase the knowledge
about the extent and nature of AEs as perceived by
CHF patients in daily practice and the strategies they
use to cope with them. We conducted this study
with the following purposes:
(1) To describe the proportion and type of perceived
AEs of CHF patients and their possible relationship
to the medication used;
(2) To describe demographic and clinical character-
istics of CHF patients who perceive AEs;
(3) To describe strategies undertaken by CHF
patients in response to the perceived AEs.
Methods
Patient population
Patients in this study were participants in the Coor-
dinating study evaluating Outcomes of Advising and
Counselling in heart failure (the COACH study).
This was a multicentre randomised controlled trial
designed to determine the effect of education and
counselling in CHF patients. The design and results
of the study are described elsewhere (11,12). Patients
were recruited in the COACH study between Octo-
ber 2002 and February 2005. To be eligible, patients
needed to be hospitalised for symptomatic heart fail-
ure (HF) [New York Heart Association Classification
(NYHA) II–IV], had to be older than 18 years and
had to have evidence of structural underlying heart
disease. Patients were excluded, if they underwent
invasive procedure or cardiac surgery intervention
within the last 6 months or planned to be performed
within the next 3 months; were unable to complete
questionnaires; were included in another concurrent
study or HF clinic or were unable or unwilling to
give informed consent.
Design and data collection
After written informed consent, patients randomised
to the experimental groups (n = 680) of the COACH
study were interviewed during the index hospitalisa-
tion (= baseline) by a HF nurse using a structured
questionnaire, which included questions about per-
ceived AEs. We conducted a cross-sectional observa-
tional study of this baseline survey. Ethical approval
was gained from the Central Ethics Committee and
the investigation conformed to the principles out-
lined in the Declaration of Helsinki.
Perceived adverse effects
Perceived AEs of medication were assessed by asking
first a filter question: ‘Do you experience any adverse
effect of your medication? (yes ⁄no)’. Next, a drug-
related symptom list was given with the following
potential adverse drug events: nausea, dizziness,
problems with sleep, headache, rash, itching, impo-
tence, cough, cold extremities and constipation.
Patients were also given the opportunity to specify
any other AE they experienced which was not on the
list.
Undertaken actions
Patients who reported any AE were asked which
action they had undertaken in response to the expe-
rienced AE. Possible answers provided were: doing
nothing, discussing it with the doctor, decreasing the
dose of the medication, discontinuing the medication
or other actions besides those listed.
Potentially related medication
Information about medication therapy taken at dis-
charge was collected by chart review. Medications
were categorised as ‘potentially related’ to an AE, if
the reported AE was consistent with the known AE
profile of that particular medication according to the
Dutch Drug Compendium (Farmacotherapeutic
Kompas). Reported AEs that could not be related to
any medication taken were categorised as ‘improba-
ble’.
Demographic and clinical data
Data on demographic and clinical variables were col-
lected by patient interviews and review of medical
records. Demographic data included age, gender, liv-
ing status (living alone or not) and educational level
(no education ⁄ primary school, secondary school and
higher education ⁄university). Quality of life was
assessed with the validated Medical Outcome Study
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36-item General Health Survey (RAND-36), a self
reported generic questionnaire of general health sta-
tus. Clinical variables consisted of duration of heart
failure, left ventricular ejection fraction (LVEF),
NYHA functional class at discharge (II–IV), aetiology
of HF, measurements of blood pressure (BP), serum
electrolytes and estimated glomular filtration rate
(eGFR) at discharge, number of comorbidities (as
categorical variable: 0, 1–2, 3–4, ‡ 5 comorbidities)
and presence of specific comorbidities (vascular dis-
orders, respiratory disorders, diabetes, gastrointesti-
nal disorders, stroke, renal ⁄urinary disorders,
musculoskeletal disorders and ⁄or neoplasms).
Statistical analysis
Continuous variables are summarised as mean
value ± standard deviation and categorical data are
presented as percentages. For the most commonly
used medication classes, potentially related AEs are
reported in absolute numbers and percentages. Data
are only presented for those medications taken by
at least 10 patients. For the descriptive analysis as
well as univariate and multivariate analyses, medica-
tion was grouped at therapeutic level. For the antiar-
rhythmic agents, this includes only class I and III
antiarrhythmics.
Differences in demographic and clinical character-
istics between reporters of AEs and non-reporters
were tested with v2 tests or Fisher’s exact tests for
dichotomuous variables. Two-tailed t-tests were used
for normally distributed data and the Mann–Whit-
ney U-test for non-parametric data. Furthermore, we
tested for differences in BP, serum electrolytes and
eGFR between reporters and non-reporters of spe-
cific AEs. In more detail, we looked for BP, sodium
and potassium as a proxy for headache and dizziness
and for eGFR as a proxy for itches. Multivariable
logistic regression analysis was conducted to investi-
gate the relationship of variables found to be signifi-
cant in the univariate analysis. All data




Of the 680 patients, 670 patients provided data dur-
ing the interview. The mean age was 70 years, 63%
were men and 55% had no education or only pri-
mary school (Table 1). Over 43% of the patients had
NYHA Class IV at admission and the mean LVEF
was 33% (± 14%). The main aetiology of HF was
ischaemic heart disease. A majority of patients
received diuretics and angiotensin converting enzyme
(ACE)-inhibitors; beta-blockers were used by 66%,
anticoagulants by 62% and lipid-lowering agents by
39%, including 37% using statins (Table 1).
Perceived adverse effects
Of the 670 patients who completed the question-
naire, 116 patients (17%) reported at least one AE of
medication, resulting in a total of 186 AEs that
patients related to their medication (Table 2). The
number of reported AEs ranged from 1 to 6 per
patients; 44 patients reported two or more different
AEs. The most prevalent reported AEs were dizziness,
nausea, itches and rash. Cough was reported by only
1.5% of the patients in this sample. Patients experi-
enced a wide variety of other AEs besides those listed
with the most frequently being other gastrointestinal
problems, dry mouth and less appetite.
Potentially related medication
Of the 186 reported AEs, 28 (15%) were classified as
improbable, meaning that the reported AEs could
not be related to any medication taken. The most
commonly ‘improbable’ reported AEs were itches
and impotence, which were reported by seven and
three patients, respectively, who did not take any
medication that could be linked with itches and
impotence. In total, 52 different classes of medication
could be related to the remaining 158 reported AEs.
Rates of potentially related AEs for commonly pre-
scribed cardiovascular and antithrombotic medica-
tion, i.e. prescribed to more than 10 patients in our
study population, ranged from 3 to 27% (Table 3).
Medications with high rates were pravastatin, dipyri-
damol, ramipril and amlodipine. Pravastatin was the
third most commonly prescribed agent within the
drug class lipid-lowering agents, being prescribed to
60 patients, respectively (Table 3). Ramipril, amlodi-
pine and dipyridamol were prescribed to 62, 40 and
12 patients, respectively.
Most drugs were related to several AEs, with pra-
vastatin, atorvastatin and metoprolol being the drugs
related to at least six different AEs. Nausea was
found in combination with all included medication
classes except angiotensin receptor blockers (ARBs).
Dizziness was common for all antihypertensive and
lipid-lowering agents. Adverse effects, such as head-
ache, rash, sleeping problems and constipation
showed no consistent relation with a specific medica-
tion class. Itches were observed in relation to ACE-
inhibitors but more frequently in relation to other
medications not included in Table 3, such as salme-
terol, oral blood glucose lowering medication and
proton-pump-inhibitors. Adverse effects that can be
uniquely linked to a drug class, i.e. cough for
ACE-inhibitors and ARBs and cold extremities for
beta receptor blockers, were reported by up to 7% of
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patients using these drugs. In 50% of the cases,
patients were already using these drugs for more
than 1 month, with a mean use of 1258 days
(± 1940).
For patients reporting headache, nausea or dizzi-
ness, on average, more than five different medica-
tions could be related to these AEs (Figure 1). In one
case, a patient used 11 different medications that
could all be linked to the reported AE ‘nausea’.
Factors related to perceived adverse effects
Patients reporting AEs had a lower general health
perception compared with patients not reporting AEs
(Table 4). On the other eight subscales, representing
other dimensions of quality of life, there were no sig-
nificant differences. Furthermore, patients reporting
AEs were younger than non-reporters and patients
on antiarrhythmics reported more often AEs. None
of the other demographic or clinical factors was
found to be associated in the univariate analysis. In
the multivariate logistic regression, age (OR = 0.98,
95% CI: 0.96–0.99), antiarrhythmic drug use
(OR = 2.29, 95% CI: 1.29–4.05) and general health
Table 1 Demographic and clinical characteristics of the
HF population
n = 670
% or mean ± SD
Demographics
Age (years) 70.4 ± 11.5
Gender (female) 37
Educational Level
No education ⁄ primary school 55
Secondary school 27
Higher education ⁄ university 17
Living alone 39
Clinical characteristics
Duration of heart failure (years) 1.5 ± 3.4











‡ 5 comorbidities 4
Vascular disorders 56
Respiratory disorders (COPD ⁄ Asthma) 31
Diabetes 28
Gastrointestinal disorders 13
Stroke (CVA – TIA) 17
Renal and urinary disorders 8
Musculoskeletal disorders 8
Neoplasms (benign, malignant) 4
Medication burden 7.5 ± 2.8










Table 1 (continued )
n = 670
% or mean ± SD
Other medication








Data are presented as mean ± SD or in percentages. *Antiar-
rhythmic agents include class 1 and III antiarrhythmics. COPD,
chronic obstructive pulmonary disease; LVEF, left ventricular
ejection fraction; NYHA, New York Heart Association Classifica-
tion; ARBs, angiotensin receptor blockers; HF, heart failure;
CVA, cerebrovascular accident; TIA, transient ischemic attack.
Table 2 Reported adverse effects









Sleep disturbance 7 (1.0%)
Constipation 4 (0.6%)
Others 50 (7.5%)
Total number of reported AEs 186
AEs, adverse effects.
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Acenocoumarol 20 ⁄ 363 (6) 14 (4%) 6 (2%)
Carbasalaatcalcium 20 ⁄ 155 (13) 3 (2%) 5 (3%) 5 (3%) 3 (2%) 4 (3%)
Clopidogrel 4 ⁄ 24 (17) 1 (4%) 2 (8%) 1 (4%)
Dipyridamol 3 ⁄ 12 (25) 1 (8%) 1 (8%) 1 (8%)
Fenprocoumon 4 ⁄ 40 (10) 4 (10%)
Heartglycosides
Digoxine 26 ⁄ 199 (13) 9 (5%) 8 (4%) 3 (2%) 6 (3%)
ACE-inhibitors
Captopril 2 ⁄ 62 (3) 2 (3%)
Enalapril 13 ⁄ 93 (14) 5 (5%) 3 (3%) 1 (1%) 2 (2%) 2 (2%)
Fosinopril 15 ⁄ 70 (21) 6 (9%) 1 (1%) 2 (3%) 1 (1%) 3 (4%) 2 (3%)
Lisinopril 9 ⁄ 64 (14) 3 (5%) 2 (3%) 2 (3%) 1 (2%) 1 (2%)
Perindopril 6 ⁄ 91 (7) 1 (1%) 1 (1%) 2 (2%) 2 (2%)
Quinapril 4 ⁄ 26 (15) 1 (4%) 3 (12%)
Ramipril 14 ⁄ 62 (23) 3 (5%) 5 (8%) 1 (2%) 2 (3%) 2 (3%) 1 (2%)
ARBs
Candesartan 1 ⁄ 16 (6) 1 (6%)
Losartan 6 ⁄ 41 (15) 2 (5%) 3 (7%) 1 (2%)
Beta-blockers
Atenolol 1 ⁄ 25 (4) 1 (4%)
Bisoprolol 10 ⁄ 86 (12) 4 (5%) 1 (1%) 1 (1%) 2 (2%) 2 (2%)
Carvedilol 9 ⁄ 91 (10) 1 (1%) 5 (5%) 1 (1%) 1 (1%) 1 (1%)
Metoprolol 35 ⁄ 182 (19) 6 (3%) 6 (3%) 3 (2%) 2 (1%) 5 (3%) 2 (1%) 6 (3%) 5 (3%)
Sotalol 3 ⁄ 31 (10) 2 (6%) 1 (3%)
Calcium channel blockers
Verapamil 1 ⁄ 21 (5) 1 (5%)
Diltiazem 2 ⁄ 21 (10) 1 (5%) 1 (5%)
Amlodipine 9 ⁄ 40 (23) 2 (5%) 2 (5%) 2 (5%) 2 (5%) 1 (3%)
Lipid-lowering agents
Atorvastatine 15 ⁄ 68 (22) 5 (7%) 4 (6%) 2 (3%) 1 (1%) 2 (3%) 1 (1%)
Simvastatine 10 ⁄ 108 (9) 3 (3%) 2 (2%) 3 (3%) 2 (2%)
Pravastatine 16 ⁄ 60 (27) 3 (5%) 2 (3%) 5 (8%) 1 (2%) 1 (2%) 1 (2%) 3 (5%)
Antiarrhythmic agents
Amiodaron 13 ⁄ 64 (20) 2 (3%) 4 (6%) 2 (3%) 2 (3%) 3 (5%)
Diuretics
Bumetanide 12 ⁄ 305 (4) 9 (3%) 3 (1%)
Furosemide 21 ⁄ 283 (7) 15 (5%) 6 (2%)
Spironolactone 31 ⁄ 343 (9) 13 (4%) 13 (4%) 3 (1%) 2 (1%)
Nitrates
Nitroglycerine oromusc 2 ⁄ 21 (10) 1 (5%) 1 (5%)
Nitroglycerine transd 1 ⁄ 18 (6) 1 (6%)
Isosorbide-5-mononitrate 10 ⁄ 144 (7) 5 (3%) 3 (2%) 2 (1%)
Isosorbidenitrate 7 ⁄ 54 (13) 4 (7%) 2 (4%) 1 (2%)
*A medication was excluded if fewer than 10 patients were taking that medication. Antiarrhythmic agents include class I and III antiarrhythmics. AE, adverse effect;
ARBs, angiotensin receptor blockers.
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perception (OR = 0.98, 95% CI: 0.97–0.99) were all
identified as independent predictors of perceiving
AEs in CHF patients. No significant differences were
seen between patients reporting specific AEs and the
other patients regarding BP, serum electrolytes or
eGFR (data not shown).
Undertaken actions
Of patients experiencing an AE, 69% discussed this
with the doctor and 24% reported having done noth-
ing in reaction. Four patients (3%) discontinued the
medication, half of whom having not discussed the
AE with their doctor. None of the patients reported
having reduced the dose of their medication
(Figure 2). Eleven patients (9%) reported another
strategy to deal with the experienced AE, such as dis-
cussing the AE with the HF nurse or taking addi-
tional medication to alleviate the symptoms (e.g.
skin cream or analgesics).
Discussion
To our knowledge, this is the first survey examining
perceived AEs of medication in a cohort of CHF
patients. This study shows that one out of six CHF
patients may perceive AEs of medication, with the
most prevalent being nausea, dizziness, itches and
rash. Besides the listed AEs, CHF patients reported a
high number of other perceived AEs. Although some
AEs appeared to be related to specific medication
classes, the relation between the most reported AEs
and medication was diffuse. For the most commonly
experienced AEs, at least five drugs per patient could
be identified as being potentially related. Of the 186
reported AEs, 15% could not be linked to any medi-
cation taken. There were only a few differences in
clinical and demographic characteristics between
reporters and non-reporters of AEs, but reporters did
have a lower general health perception. Finally,
one-third of the patients appeared not to have
communicated the perceived AE with their health-
care provider.
The observed overall rate of AEs of 17% in this
study is similar to that seen in the survey studies in
other patient groups (13,14), but higher than that
detected in an observational study that did not use
patient reports but a combination of review of hospi-
tal discharge notes, computer-generated signals and
reports from healthcare providers (15). Looking at
specific medication, rates were also higher than those
observed in clinical trials with these drugs, where
AEs were reported in around 10% or less patients
(16,17). This can be explained by several reasons.
First, in clinical trials, a commonly used parameter
of safety reporting is the number of withdrawals or
discontinuations of study treatment because of AEs
(4,16). In our study, as in other surveys, AEs are
those perceived by patients regardless of their conse-
quences for treatment continuation. Second, there
are differences between patients enrolled in trials and
those in actual practice. Patients in this sample are
exposed to complex medication regimens. Several
studies showed an increase in AEs when the study
medication is taken in patients with background
medication (18) or when multidrug therapies are ini-
tiated (16). Finally, it has been suggested that
patients participating in medication trials are health-
ier and have a higher tolerance for AEs and more
positive drug attitudes compared with patients in



































































Figure 1 Mean associated medication per reported adverse effect within one patient
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drugs, pravastatin was found to be the drug most
associated with reported AEs in our study. This is of
interest given to the recent discussion about the
value of statins in older patients with moderate-to-
severe heart failure following from the results of the
CORONA trial (19). However, one should keep in
mind that the most commonly reported AEs for pra-
vastatin (nausea and dizziness) are often also linked
to alternative drugs.
In our study, on average, more than five different
medications in one patient could be associated to the
reported AEs such as headache, dizziness and nausea.
Polypharmacy is a well-recognised problem in elderly
people (20) as in CHF patients (21). Consequently,




(n = 554) p-value
Demographics
Age (years) 68 ± 12 71 ± 11 0.010*
Gender (female) 38% 36% 0.74
Educational level
No education ⁄ primary school 64% 53% 0.72
Secondary school 24% 28%
Higher education ⁄ university 12% 18%
Living alone 37% 39% 0.75
RAND-36
General Health Perception 38 ± 18 45 ± 19 0.001
Clinical characteristics
LVEF (%) 35 ± 15 33 ± 14 0.43
NYHA (at discharge)
II–III 97% 97% 0.50
IV 3% 3%
Duration of heart failure (years) 2.5 ± 3.7 2.7 ± 4.4 0.36
Number of comorbidities 1.9 ± 1.5 1.8 ± 1.4 0.71
Comorbidities
Diabetes 24% 28% 0.42
Hypertension 46% 41% 0.31
COPD 32% 26% 0.18
Gastrointestinal disorders 12% 13% 0.75
Stroke (CVA – TIA) 16% 14% 0.56
Renal and urinary disorders 12% 7% 0.06
Medication burden 7.7 ± 2.8 7.4 ± 2.8 0.41*
HF Medication at discharge
ACE-inhibitors 69% 75% 0.15
ARBs 15% 10% 0.08
Beta blockers 65% 67% 0.80
Diuretics 97% 96% 0.80
Digoxine 31% 30% 0.85
Other medication
Calcium channel blockers 17% 14% 0.38
Nitrates 32% 31% 0.88
Alfa-1-receptorblocker 1% 1% 0.10
Lipid-lowering agents 45% 37% 0.12
Antiplatelet drugs 30% 33% 0.53
Anticoagulants 65% 61% 0.34
Antiarrhythmic agents§ 20% 9% 0.001
Antianginals agents 1% 0.5% 0.43
*T-test for continuous variables. Score between 0–100 and a higher score represent better health. Non-parametric test: Mann–
Whitney U-Test. Two-tailed Fisher’s exact test or v2 test for binomial variables. §Antiarrhythmic agents include class I and
class III antiarrhythmics. LVEF, left ventricular ejection fraction; NYHA, New York Heart Association Classification; COPD, chronic
obstructive pulmonary disease; ARBs, angiotensin receptor blockers; CVA, cerebrovascular accident; TIA, transient ischemic attack.
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both evaluation of reported AEs and identification of
the causal agent become a complex task in clinical
practice. Research suggests that CHF patients have
difficulty in differentiating heart failure symptoms
from adverse drug events (22). Our study, however,
shows that most of the perceived AEs could be
attributed to the drug therapy used. Although we
cannot make a causality assessment in this cross-sec-
tional study, this implies that they could represent
valid drug-symptom associations. Many patients
experiencing dizziness used one or more drugs that
may cause orthostatic hypotension. Patients experi-
encing cold extremities were almost all using beta
blocking agents. Cough, thought to be frequently
experienced in patients with heart failure by health-
care professionals in daily practice, however, was
only reported by 1.5% of the patients in this sample.
In all but one case, these were patients using ACE-
inhibitors or ARBs. On the other hand, it is likely
that some of the reported AEs are not caused by a
drug. This phenomenon also occurs in clinical trials,
where patients discontinue taking placebo because of
medication-attributed AEs (5). In our study, 15% of
the reported AEs were classified as improbable as
they could not be related to any medication.
In this study, patients who reported an AE scored
lower on the general health perception dimension of
the RAND-36. Although the impact of ‘minor’ AEs
on quality of life may be underestimated in clinical
practice, they can cause additional worries and dis-
comfort (23). We expect that perceived AEs can have
an impact on the general health perception of
patients (24). However, we cannot exclude that
patients with a more negative health perception are
more susceptible to perceiving AEs. Furthermore,
using an antiarrhythmic drug regimen and younger
age were also associated with reporting of AEs. Ami-
odarone is the most commonly prescribed antiar-
rhythmic drug and known for many potential AEs
(25,26). The finding that younger age was related to
perceiving more AEs was somewhat surprising,
although studies in other patient groups also did not
find any relationship between patient characteristics,
such as age, gender, educational level, number of
coexisting conditions, number of medications and
rates of reported AEs (13,27). These findings are in
contrast with studies looking at documented or veri-
fied adverse drug events that did show associations
with age, number of comorbidities and number of
medications in different populations (20,28,29).
These disparate results suggest that although the risk
of developing specific adverse drug events can be
higher in certain patient populations, in patients
with CHF socio-demographic and clinical variables
have little capability in predicting the risk of per-
ceived AEs. A possible explanation could be that
most of the patients in our CHF cohort are rather
old (on average 70 years), with multiple comorbidi-
ties and using many drugs and are therefore all at
increased risk for experiencing AEs (27).
Studies focussing on factors influencing compli-
ance behaviour in CHF identified AEs as one of the
barriers to medication adherence (6,7). However,
patients in our study did not report decreasing their
dosage and only a few discontinued their medication
because of experiencing an AE. This low rate could
partly be because of our method of assessment,
which was based on patient self-report and may
therefore underestimate the true prevalence of non-
compliance (30–32). On the other hand, heart failure
is known to be associated with high mortality and
with a high symptom burden. Therefore, these
patients might be willing to endure certain AEs.
Despite the low translation of symptom burden in
non-compliance, the importance and value of these
‘subjective’ reported AEs remain. Indeed, the most
perceived AEs are symptoms that do not endanger
the health of the patient severely and may therefore
not be taken seriously from a medico-technical point
of view. However, from the patient perspective, these
medically-minor symptoms may add substantially to
the disease burden and cause subjective distress (23).
In our study, 71% of the included CHF patients
discussed perceived AEs with a healthcare profes-
sional. This is consistent with the other studies show-
ing 69% up to 85% of patients who communicated
their concerns with a healthcare professional (14,33).
The failure to discuss medication problems with the
physician can result in ameliorable and preventable
adverse drug events (14). Possible explanations for
this failure to communicate can be that patients do



































Figure 2 Actions undertaken by patients in response to
perceived adverse effects
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perceived symptoms as an unavoidable phenomenon
of ageing or they find a way to manage certain AEs
and accept them. Managing perceived AEs in clinical
practice, therefore, seems to be best served by an
individualised approach in face-to-face encounters
with the healthcare professional. This patient-centred
approach is considered a cornerstone of care (34).
By nurse or doctor interaction, patients can be made
more aware of potential AEs at the moment a new
drug is initiated. This may contribute to good
patient compliance and may facilitate early recogni-
tion of AEs.
This study is the first in describing perceived AEs
in CHF and has some limitations. The cross-sec-
tional nature of the design precludes any attempt to
establish the direction of causality. Although we
excluded cases where the medication was started
after the AE report, we could not perform a causality
assessment based on the exact timing of events. We
acknowledge the possibility that some of the
reported AEs may be the result of heart failure or
other concurrent diseases rather than of the medica-
tion itself. However, patients themselves reported
these as AEs of their medication and one should
keep in mind that the subjective perceived AE by
patients can be as important to adherence, distress
and quality of life as when the association between
the drug and the effect is objectively confirmed. Sec-
ondly, perceived AEs were determined by using an
open-ended question as filter followed by a checklist
of potential adverse drug events. In the literature,
there is no consistency or gold standard as regards
how to elicit perceived AEs. Open questioning can
underestimate patients’ experiences of perceived AEs
(35). On the contrary, symptom checklists can
increase the number of reported AEs by suggestion
and are therefore likely to have low specificity for
detecting true adverse drug events (35). However,
our results as well as those from another study
showed that patients are most likely to report symp-
toms which could be related to a high probability to
medicines and are in line with the known AE pro-
files of the drugs prescribed (36). Because of rela-
tively small numbers of patients reporting specific
AEs, the power to detect differences in potentially
related measurements of BP, serum electrolytes or
eGFR was low. Finally, this study was conducted in
a patient population that had been hospitalised for
heart failure. This may have influenced the rate of
reported AEs as patients could have been exposed to
higher numbers of recent medication modifications
than in an ambulatory setting.
This study underlines the complexity of recognis-
ing and managing adverse drug events in daily prac-
tice for CHF patients, as the most prevalent reported
AEs could be related to at least four different drugs.
As it is difficult to predict who will perceive an AE
and not all patients will mention the AEs themselves,
health professionals need to actively ask for and dis-
cuss AEs with the CHF patients. Retrieving addi-
tional information on the chronology of onset as
well as the severity can help select the most fitting
among alternative options to ameliorate, counter or
cope with the AE.
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